查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1423778

进行性多灶性白质脑病变治疗的全球市场-全球产业分析、规模、份额、成长、趋势、预测(2031)-药物类型、适应症、分销管道、地区

Progressive Multifocal Leukoencephalopathy Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region:
出版日期: | 出版商: Fairfield Market Research | 英文 208 Pages | 商品交期: 2-5个工作天内

价格
简介目录

预计 2024 年至 2031 年，进行性多灶性白质脑病变治疗的全球市场规模将稳定成长。 许多低收入和中等收入国家的爱滋病毒感染率不断上升，预计将增加对进行性多灶性白质脑病变治疗的需求。 血液恶性肿瘤盛行率的增加和进行性多灶性白质脑病变的诊断正在推动市场扩张。 爱滋病毒和癌症治疗的有利报销政策预计将刺激进行性多灶性白质脑病变治疗市场的成长。 包括抗逆转录病毒和抗病毒疗法在内的新治疗方案的引入，正在为市场新进入者创造利润丰厚的机会。 HIV 和进行性多灶性白质脑病的检测、诊断和治疗方面的进步，以及医疗设施和政府计画的改进，正在推动市场成长。

在 HIV 感染、血液恶性肿瘤和进行性多灶性白质脑病患病率上升的推动下，北美和欧洲预计将引领进行性多灶性白质脑病变治疗市场。 由于爱滋病毒感染率上升、爱滋病毒和癌症治疗率提高以及对进行性多灶性白质脑病变的认识提高，亚太市场预计将持续成长。 在低收入和中等收入经济体中，增加治疗的□□使用、获得安全有效的治疗以及准确的癌症诊断可能有助于增加进行性多灶性白质脑病变的诊断。

本报告调查了全球进行性多灶性白质脑病治疗市场，提供了市场概述、按药物类型、适应症、分销渠道、地区和进入市场的公司划分的趋势。提供了竞争趋势等资讯。

目录

第 1 章执行摘要

第 2 章市场概述

  • 市场定义与细分
  • 市场动态
  • 价值链分析
  • 波特五力分析
  • 新冠肺炎 (COVID-19) 影响分析
  • 乌克兰和俄罗斯之间衝突的影响
  • 经济概况
  • PESTLE分析

第 3 章2018-2031 年全球进行性多灶性白质脑病变治疗市场前景

  • 2018-2031 年全球进行性多灶性白质脑病变治疗市场前景，按药物类型、价值（十亿美元））
  • 2018-2031 年全球进行性多灶性白质脑病变治疗市场前景，按适应症、价值（十亿美元））
  • 2018-2031 年全球渐进式多灶性白质脑病变治疗市场展望，按分销管道划分，价值（十亿美元）
  • 2018-2031 年全球渐进式多灶性白质脑病变治疗市场前景，按地区、价值（十亿美元））

第 4 章2018-2031 年北美进行性多灶性白质脑病变治疗市场前景

第 5 章欧洲进行性多灶性白质脑病变治疗市场前景，2018-2031

第 6 章2018-2031 年亚太地区进行性多灶性白质脑病变治疗市场前景

第 7 章拉丁美洲渐进式多灶性白质脑病变治疗市场展望，2018-2031 年

第 8 章中东与非洲渐进式多灶性白质脑病变治疗市场展望，2018-2031 年

第 9 章竞争态势

  • 药品类型与通路热图
  • 製造商和分销通路热图
  • 2023 年公司市占率分析
  • 竞争对手仪表板
  • 公司简介
    • Pfizer, Inc.
    • F. Hoffman - La Roche Ltd.
    • Gilead Sciences, Inc.
    • GlaxoSmithKline plc
    • Sanofi S.A.
    • Allergan plc
    • Novartis AG
    • Mylan N.V.
    • AbbVie Inc.
    • Bristol-Myers Squibb Company

第 10 章附录

简介目录

The global progressive multifocal leukoencephalopathy treatment market is set to experience steady growth from 2024 to 2031. Several key insights are driving this growth in the market:

Factors Driving Market Growth:

  • Rising HIV Prevalence: The growing prevalence of HIV infection in many middle- and low-income countries is expected to fuel the demand for progressive multifocal leukoencephalopathy treatment.
  • Hematological Malignancies: An increasing incidence of hematological malignancies and the diagnosis of progressive multifocal leukoencephalopathy are driving the market's expansion.
  • Favorable Reimbursements: Favorable reimbursement policies for HIV and cancer treatments are expected to stimulate growth in the progressive multifocal leukoencephalopathy treatment market.
  • Emerging Treatment Options: The introduction of emerging treatment options, including anti-retroviral and antiviral therapies, is creating lucrative opportunities for new entrants in the market.
  • Healthcare Infrastructure Improvement: Advances in HIV and progressive multifocal leukoencephalopathy testing, diagnosis, and treatment, along with improved healthcare facilities and government programs, are boosting market growth.

Regional Outlook:

  • North America: North America, followed by Europe, is anticipated to lead the progressive multifocal leukoencephalopathy treatment market, driven by the increasing prevalence of HIV infection, hematological malignancies, and progressive multifocal leukoencephalopathy.
  • Asia-Pacific: The Asia-Pacific market is expected to witness continuous growth due to the rising HIV infection rates, improving treatment rates for HIV and cancer, and increasing awareness about progressive multifocal leukoencephalopathy.
  • Middle East & Africa: Growing treatment-seeking rates in middle- and low-income economies, along with access to safe and effective treatment and accurate cancer diagnosis, will likely contribute to increased progressive multifocal leukoencephalopathy diagnoses.

Opportunities for Growth:

  • Antiviral Agents: The use of antiviral agents, immune response modulators, and immunization treatment for potential progressive multifocal leukoencephalopathy patients is expected to drive market growth.
  • Research and Development: Emphasis on researching and developing drugs and therapies for rare diseases presents a significant opportunity for the progressive multifocal leukoencephalopathy treatment market.
  • Innovative Therapies: Companies are exploring innovative therapies to control JC virus infection rather than improving immunity, which is likely to spur market growth.
  • Improvement in Available Treatments: Leading companies in the progressive multifocal leukoencephalopathy treatment market are focusing on enhancing available treatment options.

Key Players:

Some of the key players in the global progressive multifocal leukoencephalopathy treatment market include Pfizer, Inc., GlaxoSmithKline Plc, Sanofi S.A., Gilead Sciences, Inc., Allergan Plc. (Actavis Plc.), Novartis AG, F. Hoffman - La Roche Ltd., AbbVie Inc., and Bristol-Myers Squibb Company, among others.

Table of Contents

1. Executive Summary

  • 1.1. Global Progressive Multifocal Leukoencephalopathy Treatment Market Snapshot
  • 1.2. Future Projections
  • 1.3. Key Market Trends
  • 1.4. Regional Snapshot, by Value, 2023
  • 1.5. Analyst Recommendations

2. Market Overview

  • 2.1. Market Definitions and Segmentations
  • 2.2. Market Dynamics
    • 2.2.1. Drivers
    • 2.2.2. Restraints
    • 2.2.3. Market Opportunities
  • 2.3. Value Chain Analysis
  • 2.4. Porter's Five Forces Analysis
  • 2.5. COVID-19 Impact Analysis
    • 2.5.1. Supply
    • 2.5.2. Demand
  • 2.6. Impact of Ukraine-Russia Conflict
  • 2.7. Economic Overview
    • 2.7.1. World Economic Projections
  • 2.8. PESTLE Analysis

3. Global Progressive Multifocal Leukoencephalopathy Treatment Market Outlook, 2018 - 2031

  • 3.1. Global Progressive Multifocal Leukoencephalopathy Treatment Market Outlook, by Drug Type, Value (US$ Bn), 2018 - 2031
    • 3.1.1. Key Highlights
      • 3.1.1.1. Anti-retroviral Therapy
      • 3.1.1.2. Antiviral/Anti JCV
      • 3.1.1.3. Other Symptomatic
  • 3.2. Global Progressive Multifocal Leukoencephalopathy Treatment Market Outlook, by Indication, Value (US$ Bn), 2018 - 2031
    • 3.2.1. Key Highlights
      • 3.2.1.1. HIV/AIDS
      • 3.2.1.2. Organ Transplantation
      • 3.2.1.3. Multiple Sclerosis
      • 3.2.1.4. Hematological Malignancies
  • 3.3. Global Progressive Multifocal Leukoencephalopathy Treatment Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 3.3.1. Key Highlights
      • 3.3.1.1. Hospital Pharmacies
      • 3.3.1.2. Drug Stores
      • 3.3.1.3. Retail Pharmacies
  • 3.4. Global Progressive Multifocal Leukoencephalopathy Treatment Market Outlook, by Region, Value (US$ Bn), 2018 - 2031
    • 3.4.1. Key Highlights
      • 3.4.1.1. North America
      • 3.4.1.2. Europe
      • 3.4.1.3. Asia Pacific
      • 3.4.1.4. Latin America
      • 3.4.1.5. Middle East & Africa

4. North America Progressive Multifocal Leukoencephalopathy Treatment Market Outlook, 2018 - 2031

  • 4.1. North America Progressive Multifocal Leukoencephalopathy Treatment Market Outlook, by Drug Type, Value (US$ Bn), 2018 - 2031
    • 4.1.1. Key Highlights
      • 4.1.1.1. Anti-retroviral Therapy
      • 4.1.1.2. Antiviral/Anti JCV
      • 4.1.1.3. Other Symptomatic
  • 4.2. North America Progressive Multifocal Leukoencephalopathy Treatment Market Outlook, by Indication, Value (US$ Bn), 2018 - 2031
    • 4.2.1. Key Highlights
      • 4.2.1.1. HIV/AIDS
      • 4.2.1.2. Organ Transplantation
      • 4.2.1.3. Multiple Sclerosis
      • 4.2.1.4. Hematological Malignancies
  • 4.3. North America Progressive Multifocal Leukoencephalopathy Treatment Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 4.3.1. Key Highlights
      • 4.3.1.1. Hospital Pharmacies
      • 4.3.1.2. Drug Stores
      • 4.3.1.3. Retail Pharmacies
  • 4.4. North America Progressive Multifocal Leukoencephalopathy Treatment Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
    • 4.4.1. Key Highlights
      • 4.4.1.1. U.S. Progressive Multifocal Leukoencephalopathy Treatment Market by Drug Type, Value (US$ Bn), 2018 - 2031
      • 4.4.1.2. U.S. Progressive Multifocal Leukoencephalopathy Treatment Market by Indication, Value (US$ Bn), 2018 - 2031
      • 4.4.1.3. U.S. Progressive Multifocal Leukoencephalopathy Treatment Market Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 4.4.1.4. Canada Progressive Multifocal Leukoencephalopathy Treatment Market by Drug Type, Value (US$ Bn), 2018 - 2031
      • 4.4.1.5. Canada Progressive Multifocal Leukoencephalopathy Treatment Market by Indication, Value (US$ Bn), 2018 - 2031
      • 4.4.1.6. Canada Progressive Multifocal Leukoencephalopathy Treatment Market Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 4.4.2. BPS Analysis/Market Attractiveness Analysis

5. Europe Progressive Multifocal Leukoencephalopathy Treatment Market Outlook, 2018 - 2031

  • 5.1. Europe Progressive Multifocal Leukoencephalopathy Treatment Market Outlook, by Drug Type, Value (US$ Bn), 2018 - 2031
    • 5.1.1. Key Highlights
      • 5.1.1.1. Anti-retroviral Therapy
      • 5.1.1.2. Antiviral/Anti JCV
      • 5.1.1.3. Other Symptomatic
  • 5.2. Europe Progressive Multifocal Leukoencephalopathy Treatment Market Outlook, by Indication, Value (US$ Bn), 2018 - 2031
    • 5.2.1. Key Highlights
      • 5.2.1.1. HIV/AIDS
      • 5.2.1.2. Organ Transplantation
      • 5.2.1.3. Multiple Sclerosis
      • 5.2.1.4. Hematological Malignancies
  • 5.3. Europe Progressive Multifocal Leukoencephalopathy Treatment Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 5.3.1. Key Highlights
      • 5.3.1.1. Hospital Pharmacies
      • 5.3.1.2. Drug Stores
      • 5.3.1.3. Retail Pharmacies
  • 5.4. Europe Progressive Multifocal Leukoencephalopathy Treatment Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
    • 5.4.1. Key Highlights
      • 5.4.1.1. Germany Progressive Multifocal Leukoencephalopathy Treatment Market by Drug Type, Value (US$ Bn), 2018 - 2031
      • 5.4.1.2. Germany Progressive Multifocal Leukoencephalopathy Treatment Market by Indication, Value (US$ Bn), 2018 - 2031
      • 5.4.1.3. Germany Progressive Multifocal Leukoencephalopathy Treatment Market Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 5.4.1.4. U.K. Progressive Multifocal Leukoencephalopathy Treatment Market by Drug Type, Value (US$ Bn), 2018 - 2031
      • 5.4.1.5. U.K. Progressive Multifocal Leukoencephalopathy Treatment Market by Indication, Value (US$ Bn), 2018 - 2031
      • 5.4.1.6. U.K. Progressive Multifocal Leukoencephalopathy Treatment Market Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 5.4.1.7. France Progressive Multifocal Leukoencephalopathy Treatment Market by Drug Type, Value (US$ Bn), 2018 - 2031
      • 5.4.1.8. France Progressive Multifocal Leukoencephalopathy Treatment Market by Indication, Value (US$ Bn), 2018 - 2031
      • 5.4.1.9. France Progressive Multifocal Leukoencephalopathy Treatment Market Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 5.4.1.10. Italy Progressive Multifocal Leukoencephalopathy Treatment Market by Drug Type, Value (US$ Bn), 2018 - 2031
      • 5.4.1.11. Italy Progressive Multifocal Leukoencephalopathy Treatment Market by Indication, Value (US$ Bn), 2018 - 2031
      • 5.4.1.12. Italy Progressive Multifocal Leukoencephalopathy Treatment Market Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 5.4.1.13. Turkey Progressive Multifocal Leukoencephalopathy Treatment Market by Drug Type, Value (US$ Bn), 2018 - 2031
      • 5.4.1.14. Turkey Progressive Multifocal Leukoencephalopathy Treatment Market by Indication, Value (US$ Bn), 2018 - 2031
      • 5.4.1.15. Turkey Progressive Multifocal Leukoencephalopathy Treatment Market Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 5.4.1.16. Russia Progressive Multifocal Leukoencephalopathy Treatment Market by Drug Type, Value (US$ Bn), 2018 - 2031
      • 5.4.1.17. Russia Progressive Multifocal Leukoencephalopathy Treatment Market by Indication, Value (US$ Bn), 2018 - 2031
      • 5.4.1.18. Russia Progressive Multifocal Leukoencephalopathy Treatment Market Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 5.4.1.19. Rest of Europe Progressive Multifocal Leukoencephalopathy Treatment Market by Drug Type, Value (US$ Bn), 2018 - 2031
      • 5.4.1.20. Rest of Europe Progressive Multifocal Leukoencephalopathy Treatment Market by Indication, Value (US$ Bn), 2018 - 2031
      • 5.4.1.21. Rest of Europe Progressive Multifocal Leukoencephalopathy Treatment Market Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 5.4.2. BPS Analysis/Market Attractiveness Analysis

6. Asia Pacific Progressive Multifocal Leukoencephalopathy Treatment Market Outlook, 2018 - 2031

  • 6.1. Asia Pacific Progressive Multifocal Leukoencephalopathy Treatment Market Outlook, by Drug Type, Value (US$ Bn), 2018 - 2031
    • 6.1.1. Key Highlights
      • 6.1.1.1. Anti-retroviral Therapy
      • 6.1.1.2. Antiviral/Anti JCV
      • 6.1.1.3. Other Symptomatic
  • 6.2. Asia Pacific Progressive Multifocal Leukoencephalopathy Treatment Market Outlook, by Indication, Value (US$ Bn), 2018 - 2031
    • 6.2.1. Key Highlights
      • 6.2.1.1. HIV/AIDS
      • 6.2.1.2. Organ Transplantation
      • 6.2.1.3. Multiple Sclerosis
      • 6.2.1.4. Hematological Malignancies
  • 6.3. Asia Pacific Progressive Multifocal Leukoencephalopathy Treatment Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 6.3.1. Key Highlights
      • 6.3.1.1. Hospital Pharmacies
      • 6.3.1.2. Drug Stores
      • 6.3.1.3. Retail Pharmacies
  • 6.4. Asia Pacific Progressive Multifocal Leukoencephalopathy Treatment Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
    • 6.4.1. Key Highlights
      • 6.4.1.1. China Progressive Multifocal Leukoencephalopathy Treatment Market by Drug Type, Value (US$ Bn), 2018 - 2031
      • 6.4.1.2. China Progressive Multifocal Leukoencephalopathy Treatment Market by Indication, Value (US$ Bn), 2018 - 2031
      • 6.4.1.3. China Progressive Multifocal Leukoencephalopathy Treatment Market Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 6.4.1.4. Japan Progressive Multifocal Leukoencephalopathy Treatment Market by Drug Type, Value (US$ Bn), 2018 - 2031
      • 6.4.1.5. Japan Progressive Multifocal Leukoencephalopathy Treatment Market by Indication, Value (US$ Bn), 2018 - 2031
      • 6.4.1.6. Japan Progressive Multifocal Leukoencephalopathy Treatment Market Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 6.4.1.7. South Korea Progressive Multifocal Leukoencephalopathy Treatment Market by Drug Type, Value (US$ Bn), 2018 - 2031
      • 6.4.1.8. South Korea Progressive Multifocal Leukoencephalopathy Treatment Market by Indication, Value (US$ Bn), 2018 - 2031
      • 6.4.1.9. South Korea Progressive Multifocal Leukoencephalopathy Treatment Market Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 6.4.1.10. India Progressive Multifocal Leukoencephalopathy Treatment Market by Drug Type, Value (US$ Bn), 2018 - 2031
      • 6.4.1.11. India Progressive Multifocal Leukoencephalopathy Treatment Market by Indication, Value (US$ Bn), 2018 - 2031
      • 6.4.1.12. India Progressive Multifocal Leukoencephalopathy Treatment Market Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 6.4.1.13. Southeast Asia Progressive Multifocal Leukoencephalopathy Treatment Market by Drug Type, Value (US$ Bn), 2018 - 2031
      • 6.4.1.14. Southeast Asia Progressive Multifocal Leukoencephalopathy Treatment Market by Indication, Value (US$ Bn), 2018 - 2031
      • 6.4.1.15. Southeast Asia Progressive Multifocal Leukoencephalopathy Treatment Market Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 6.4.1.16. Rest of Asia Pacific Progressive Multifocal Leukoencephalopathy Treatment Market by Drug Type, Value (US$ Bn), 2018 - 2031
      • 6.4.1.17. Rest of Asia Pacific Progressive Multifocal Leukoencephalopathy Treatment Market by Indication, Value (US$ Bn), 2018 - 2031
      • 6.4.1.18. Rest of Asia Pacific Progressive Multifocal Leukoencephalopathy Treatment Market Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 6.4.2. BPS Analysis/Market Attractiveness Analysis

7. Latin America Progressive Multifocal Leukoencephalopathy Treatment Market Outlook, 2018 - 2031

  • 7.1. Latin America Progressive Multifocal Leukoencephalopathy Treatment Market Outlook, by Drug Type, Value (US$ Bn), 2018 - 2031
    • 7.1.1. Key Highlights
      • 7.1.1.1. Anti-retroviral Therapy
      • 7.1.1.2. Antiviral/Anti JCV
      • 7.1.1.3. Other Symptomatic
  • 7.2. Latin America Progressive Multifocal Leukoencephalopathy Treatment Market Outlook, by Indication, Value (US$ Bn), 2018 - 2031
    • 7.2.1. Key Highlights
      • 7.2.1.1. HIV/AIDS
      • 7.2.1.2. Organ Transplantation
      • 7.2.1.3. Multiple Sclerosis
      • 7.2.1.4. Hematological Malignancies
  • 7.3. Latin America Progressive Multifocal Leukoencephalopathy Treatment Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 7.3.1. Key Highlights
      • 7.3.1.1. Hospital Pharmacies
      • 7.3.1.2. Drug Stores
      • 7.3.1.3. Retail Pharmacies
  • 7.4. Latin America Progressive Multifocal Leukoencephalopathy Treatment Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
    • 7.4.1. Key Highlights
      • 7.4.1.1. Brazil Progressive Multifocal Leukoencephalopathy Treatment Market by Drug Type, Value (US$ Bn), 2018 - 2031
      • 7.4.1.2. Brazil Progressive Multifocal Leukoencephalopathy Treatment Market by Indication, Value (US$ Bn), 2018 - 2031
      • 7.4.1.3. Brazil Progressive Multifocal Leukoencephalopathy Treatment Market Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 7.4.1.4. Mexico Progressive Multifocal Leukoencephalopathy Treatment Market by Drug Type, Value (US$ Bn), 2018 - 2031
      • 7.4.1.5. Mexico Progressive Multifocal Leukoencephalopathy Treatment Market by Indication, Value (US$ Bn), 2018 - 2031
      • 7.4.1.6. Mexico Progressive Multifocal Leukoencephalopathy Treatment Market Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 7.4.1.7. Argentina Progressive Multifocal Leukoencephalopathy Treatment Market by Drug Type, Value (US$ Bn), 2018 - 2031
      • 7.4.1.8. Argentina Progressive Multifocal Leukoencephalopathy Treatment Market by Indication, Value (US$ Bn), 2018 - 2031
      • 7.4.1.9. Argentina Progressive Multifocal Leukoencephalopathy Treatment Market Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 7.4.1.10. Rest of Latin America Progressive Multifocal Leukoencephalopathy Treatment Market by Drug Type, Value (US$ Bn), 2018 - 2031
      • 7.4.1.11. Rest of Latin America Progressive Multifocal Leukoencephalopathy Treatment Market by Indication, Value (US$ Bn), 2018 - 2031
      • 7.4.1.12. Rest of Latin America Progressive Multifocal Leukoencephalopathy Treatment Market Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 7.4.2. BPS Analysis/Market Attractiveness Analysis

8. Middle East & Africa Progressive Multifocal Leukoencephalopathy Treatment Market Outlook, 2018 - 2031

  • 8.1. Middle East & Africa Progressive Multifocal Leukoencephalopathy Treatment Market Outlook, by Drug Type, Value (US$ Bn), 2018 - 2031
    • 8.1.1. Key Highlights
      • 8.1.1.1. Anti-retroviral Therapy
      • 8.1.1.2. Antiviral/Anti JCV
      • 8.1.1.3. Other Symptomatic
  • 8.2. Middle East & Africa Progressive Multifocal Leukoencephalopathy Treatment Market Outlook, by Indication, Value (US$ Bn), 2018 - 2031
    • 8.2.1. Key Highlights
      • 8.2.1.1. HIV/AIDS
      • 8.2.1.2. Organ Transplantation
      • 8.2.1.3. Multiple Sclerosis
      • 8.2.1.4. Hematological Malignancies
  • 8.3. Middle East & Africa Progressive Multifocal Leukoencephalopathy Treatment Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 8.3.1. Key Highlights
      • 8.3.1.1. Hospital Pharmacies
      • 8.3.1.2. Drug Stores
      • 8.3.1.3. Retail Pharmacies
  • 8.4. Middle East & Africa Progressive Multifocal Leukoencephalopathy Treatment Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
    • 8.4.1. Key Highlights
      • 8.4.1.1. GCC Progressive Multifocal Leukoencephalopathy Treatment Market by Drug Type, Value (US$ Bn), 2018 - 2031
      • 8.4.1.2. GCC Progressive Multifocal Leukoencephalopathy Treatment Market by Indication, Value (US$ Bn), 2018 - 2031
      • 8.4.1.3. GCC Progressive Multifocal Leukoencephalopathy Treatment Market Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 8.4.1.4. South Africa Progressive Multifocal Leukoencephalopathy Treatment Market by Drug Type, Value (US$ Bn), 2018 - 2031
      • 8.4.1.5. South Africa Progressive Multifocal Leukoencephalopathy Treatment Market by Indication, Value (US$ Bn), 2018 - 2031
      • 8.4.1.6. South Africa Progressive Multifocal Leukoencephalopathy Treatment Market Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 8.4.1.7. Egypt Progressive Multifocal Leukoencephalopathy Treatment Market by Drug Type, Value (US$ Bn), 2018 - 2031
      • 8.4.1.8. Egypt Progressive Multifocal Leukoencephalopathy Treatment Market by Indication, Value (US$ Bn), 2018 - 2031
      • 8.4.1.9. Egypt Progressive Multifocal Leukoencephalopathy Treatment Market Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 8.4.1.10. Nigeria Progressive Multifocal Leukoencephalopathy Treatment Market by Drug Type, Value (US$ Bn), 2018 - 2031
      • 8.4.1.11. Nigeria Progressive Multifocal Leukoencephalopathy Treatment Market by Indication, Value (US$ Bn), 2018 - 2031
      • 8.4.1.12. Nigeria Progressive Multifocal Leukoencephalopathy Treatment Market Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 8.4.1.13. Rest of Middle East & Africa Progressive Multifocal Leukoencephalopathy Treatment Market by Drug Type, Value (US$ Bn), 2018 - 2031
      • 8.4.1.14. Rest of Middle East & Africa Progressive Multifocal Leukoencephalopathy Treatment Market by Indication, Value (US$ Bn), 2018 - 2031
      • 8.4.1.15. Rest of Middle East & Africa Progressive Multifocal Leukoencephalopathy Treatment Market Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 8.4.2. BPS Analysis/Market Attractiveness Analysis

9. Competitive Landscape

  • 9.1. Drug Type vs Distribution Channel Heatmap
  • 9.2. Manufacturer vs Distribution Channel Heatmap
  • 9.3. Company Market Share Analysis, 2023
  • 9.4. Competitive Dashboard
  • 9.5. Company Profiles
    • 9.5.1. Pfizer, Inc.
      • 9.5.1.1. Company Overview
      • 9.5.1.2. Drug Type Portfolio
      • 9.5.1.3. Financial Overview
      • 9.5.1.4. Business Strategies and Development
    • 9.5.2. F. Hoffman - La Roche Ltd.
      • 9.5.2.1. Company Overview
      • 9.5.2.2. Drug Type Portfolio
      • 9.5.2.3. Financial Overview
      • 9.5.2.4. Business Strategies and Development
    • 9.5.3. Gilead Sciences, Inc.
      • 9.5.3.1. Company Overview
      • 9.5.3.2. Drug Type Portfolio
      • 9.5.3.3. Financial Overview
      • 9.5.3.4. Business Strategies and Development
    • 9.5.4. GlaxoSmithKline plc
      • 9.5.4.1. Company Overview
      • 9.5.4.2. Drug Type Portfolio
      • 9.5.4.3. Financial Overview
      • 9.5.4.4. Business Strategies and Development
    • 9.5.5. Sanofi S.A.
      • 9.5.5.1. Company Overview
      • 9.5.5.2. Drug Type Portfolio
      • 9.5.5.3. Financial Overview
      • 9.5.5.4. Business Strategies and Development
    • 9.5.6. Allergan plc
      • 9.5.6.1. Company Overview
      • 9.5.6.2. Drug Type Portfolio
      • 9.5.6.3. Financial Overview
      • 9.5.6.4. Business Strategies and Development
    • 9.5.7. Novartis AG
      • 9.5.7.1. Company Overview
      • 9.5.7.2. Drug Type Portfolio
      • 9.5.7.3. Financial Overview
      • 9.5.7.4. Business Strategies and Development
    • 9.5.8. Mylan N.V.
      • 9.5.8.1. Company Overview
      • 9.5.8.2. Drug Type Portfolio
      • 9.5.8.3. Financial Overview
      • 9.5.8.4. Business Strategies and Development
    • 9.5.9. AbbVie Inc.
      • 9.5.9.1. Company Overview
      • 9.5.9.2. Drug Type Portfolio
      • 9.5.9.3. Financial Overview
      • 9.5.9.4. Business Strategies and Development
    • 9.5.10. Bristol-Myers Squibb Company
      • 9.5.10.1. Company Overview
      • 9.5.10.2. Drug Type Portfolio
      • 9.5.10.3. Financial Overview
      • 9.5.10.4. Business Strategies and Development

10. Appendix

  • 10.1. Research Methodology
  • 10.2. Report Assumptions
  • 10.3. Acronyms and Abbreviations